Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Solid Tumors

About this trial
This is an interventional treatment trial for Solid Tumors focused on measuring PIK3CA, PTEN, TSC1/2, STK11, MTOR, MYC, MAPK, advanced solid tumor, advanced solid malignancies, melanoma, skin cancer, ovarian cancer, endometrium/uterus cancer, bladder cancer, cervical cancer, Carcinoma, Non-Small-Cell Lung, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Esophageal Neoplasms, Carcinoma, Bronchogenic, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Neoplasms, Glandular and Epithelial, Gastrointestinal Neoplasms, Digestive System Neoplasms, Head and Neck Neoplasms, Digestive System Diseases, Esophageal Diseases, Gastrointestinal Diseases, 4EBP1
Eligibility Criteria
Inclusion Criteria:
- Participants (male or female) ≥18 years of age
- Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Participants in the Dose-Expansion Component must have molecular aberrations in the mTOR pathway
- Adequate hematologic, hepatic and renal function
Exclusion Criteria:
- Known or suspected leptomeningeal or brain metastases or spinal cord compression
- Primary central nervous system (CNS) tumors
- Clinically significant cardiac disease
- Active, clinically significant interstitial lung disease or pneumonitis
- Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2 diabetes are excluded.
- Subjects with stomatitis or mucositis of any grade
Sites / Locations
- UC Irvine - Chao Family Comprehensive Cancer CenterRecruiting
- UC Davis Comprehensive Cancer CenterRecruiting
- UC San Francisco - Helen Diller Family Comprehensive Cancer CenterRecruiting
- Moffitt Cancer CenterRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- University of Oklahoma - Stephenson Cancer CenterRecruiting
- Sarah Cannon Research Institute - Tennessee Oncology, PLLCRecruiting
- Dell Seton Medical Center at University of TexasRecruiting
Arms of the Study
Arm 1
Experimental
RMC-5552
RMC-5552 for IV administration